Skip to content
Remus Pharmaceuticals logo

Remus Pharmaceuticals

REMUS NSE
₹819.55 −26.10 (−3.09%)
View as Markdown
MCP
Close 4 Nov 2026 ₹819.55 +8.40 +1.04% 1Y
Start ₹811.15

Key Fundamentals

SMEPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · TTM

ROCE
16.80%
Debt to Equity
0.08
EPS (TTM)
—
Book Value
₹297.86
Market Cap
—
P/E (TTM)
—
P/B
2.75
ROE
12.20%
Dividend Yield
0.12%
EBITDA
₹63.40 Cr
52W High
₹1,039.00
52W Low
₹580.00
Day Range
₹810.00 – ₹852.00
Volume
13,000

Peer Comparison

Healthcare › Pharmaceuticals

Remus Pharmaceuticals peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Remus Pharmaceuticals (this company)
₹819.55—₹990 Cr2.750.12%12.20%16.80%——
Median 8 companies₹1,587.7038.81₹1,25,337 Cr4.570.44%16.25%17.30%₹28,324 Cr₹3,184 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

47 Average

Data confidence 81/100

Category scores

Quality
36
Poor
Returns, margins, earnings quality 22% weight
Valuation
56
Good
Cheap vs sector & own history 24% weight
Growth
97
Strong
Sales & profit trajectory 9% weight
Financial Health
51
Average
Solvency, leverage, coverage 9% weight
Momentum
42
Weak
Trend strength, vol-adjusted 12% weight
Ownership
24
Poor
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Debtor days have improved from 107 to 59.8 days.
  • Company's working capital requirements have reduced from 67.1 days to 49.2 days

Weaknesses

1
  • Company has a low return on equity of 12.9% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1144
OscillatorsBullish243
Moving AveragesStrong Bearish901

Key readings

RSI (14)
37.25
Neutral
MACD (12,26,9)
−22.39
Bearish
SMA (50)
911.54
Bearish
SMA (200)
765.17
Bullish

As of

Growth Rate

From the financial statements below. 1Y: fiscal year to Mar 2026 against Mar 2025.

Revenue

Revenue growth by window
1Y+37.74%

Net profit

Net profit growth by window
1Y+21.05%

Operating cash flow

Operating cash flow growth by window
1Y+157.14%

Operating margin· change in pp

Operating margin growth by window
1Y−0.75 pp

Trailing twelve months: Results are not reported for each of the last eight quarters, so there is no trailing-twelve-month figure.

Revenue by year

Revenue by year, ₹ crore
Mar 2024₹213 Cr
Mar 2025₹620 Cr
Mar 2026₹854 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2024₹24.00 Cr
Mar 2025₹38.00 Cr
Mar 2026₹46.00 Cr

Half-yearly Results

₹ Cr
REMUS half-yearly results, ₹ crore
Particulars Sep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Sales
29
185
273
348
400
453
Expenses
20
165
252
323
373
424
Operating Profit
9
20
20
25
27
30
OPM %
32%
11%
8%
7%
7%
7%
Other Income
2
3
3
3
3
4
Interest
0
0
1
1
1
1
Depreciation
0
1
0
1
1
1
PBT
10
22
22
25
28
31
Tax %
25%
15%
16%
19%
23%
21%
Net Profit
6
19
19
21
22
25
EPS (₹)
4.87
13.16
11.87
13.57
14.85
16.54

Profit & Loss

₹ Cr
REMUS profit and loss, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Sales
213
620
854
Expenses
184
575
797
Operating Profit
29
46
57
OPM %
14%
7%
7%
Other Income
3
5
7
Interest
0
1
1
Depreciation
1
2
3
PBT
30
47
59
Tax %
20%
19%
22%
Net Profit
24
38
46
EPS (₹)
17.69
24.64
31.39
Div. Payout %
4%
3%
2%

Balance Sheet

₹ Cr
REMUS balance sheet, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Equity Capital
1
6
12
Reserves
156
250
339
Borrowings
14
23
27
Other Liabilities
161
154
201
Total Liabilities
333
433
579
Fixed Assets
14
16
18
CWIP
0
0
8
Investments
105
186
275
Other Assets
215
231
277
Total Assets
333
433
579

Cash Flow

₹ Cr
REMUS cash flow, annual, ₹ crore
Particulars Mar 2024Mar 2025Mar 2026
Operating
4
7
18
Investing
−9
−11
−15
Financing
24
6
1
Net Cash Flow
19
2
5
Free Cash Flow
3
3
4
CFO/EBITDA
35
32
49

Ratios

REMUS financial ratios, annual
Particulars Mar 2024Mar 2025Mar 2026
Debtor Days
198
64
60
Inventory Days
96
35
35
Days Payable
209
49
37
Cash Conversion Cycle
85
50
58
Working Capital Days
98
54
49
ROCE %
—
20%
17%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Remus Pharmaceuticals insights

63 extracted metrics across FY20–FY26.

Shareholding Pattern

As of Sep 2026

  • Promoters 70.95%
  • Public 18.39%
  • Others 5.13%
  • FIIs 5.10%
  • DIIs 0.43%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Remus Pharmaceuticals

What does Remus Pharmaceuticals Ltd do?
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services
Where is Remus Pharmaceuticals Ltd (REMUS) listed?
Remus Pharmaceuticals Ltd trades as REMUS on the NSE.
Which sector does Remus Pharmaceuticals Ltd belong to?
Remus Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the 52-week high and low of Remus Pharmaceuticals Ltd?
Over the last 52 weeks Remus Pharmaceuticals Ltd has traded between ₹580 and ₹1,039 as of 4 Nov 2026.
Does Remus Pharmaceuticals Ltd pay dividends?
Remus Pharmaceuticals Ltd has a dividend yield of 0.12%.
What is the Return on Equity (ROE) of Remus Pharmaceuticals Ltd?
Remus Pharmaceuticals Ltd reported a return on equity of 12.20%. Its debt-to-equity ratio is 0.08.

Company Information

Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services

Website remuspharma.com
Listed 29 May 2023
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/REMUS.md for Remus Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month